RxDoctor Payments Data

Joshua Lipschutz, MD

Nephrology · Charleston, SCNPI 1598848657

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $37,002 of the $44,124 with a category attached, or 83.9%. 6 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 58.0% of the total. Reporting peaked in 2022 at $16,257 and has fallen 98.3% since, to $277 in 2025. Among nephrology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$44,124in general payments, 2019–2025

Across 48 payments — averaging $919.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$26K
  • Otsuka America Pharmaceutical, Inc.$16K
  • Sanofi$2K
  • Mallinckrodt Hospital Products Inc.$131
  • Calliditas Therapeutics US Inc.$123
  • Alnylam Pharmaceuticals Inc.$23

What the payments were for

  • Consulting fees$2,7626%
  • Speaking & faculty fees$37,00284%
  • Travel & lodging$3,4878%
  • Food & beverage$8732%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,124 in reported general payments places this provider in the 95th percentile of 180 nephrology providers in South Carolina.

See all nephrology providers in South Carolina

Medicare billing

Part B allowed, 2024
$18,630
Medicare patients
79
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$251,027
Calcium Acetate17$1,334
Famotidine34$844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$16,144$251,02713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 nephrology providers in South Carolina.

Other nephrology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →